Avelas Biosciences is a clinical-stage biotechnology company and a pioneer in the field of intraoperative fluorescent cancer imaging. The company is focused on developing pegloprastide (also known as AVB-620), a novel drug-device combination product for use during cancer surgery. Pegloprastide is designed to improve surgery by detecting cancer in real time and has the potential to become part of standard-of-care treatment for a variety of cancer surgeries.

In a registration study in a broad population of women with primary, nonrecurrent breast cancer, use of pegloprastide during breast conserving surgery correctly identified cancer in up to 75% of women with positive margins who would have otherwise been candidates for a reoperation.

Beyond breast cancer, Avelas has plans to explore the use of pegloprastide in a subset of other cancer surgeries, including ovarian, colorectal, head and neck, melanoma, and sarcoma.

Pegloprastide has been developed by Avelas from revolutionary technology originating in the lab of Nobel Laureate Roger Y. Tsien at the University of California – San Diego. Avelas was founded by Avalon Ventures and maintains its corporate office in La Jolla, California.